

A&I

ANÄSTHESIOLOGIE & INTENSIVMEDIZIN

Offizielles Organ: Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin e. V. (DGAI)
Berufsverband Deutscher Anästhesisten e. V. (BDA)

Organ: Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin e. V. (DIVI)



Amyotrophic lateral sclerosis

Donohue syndrome

orphan**a**nesthesia

a project of the German Society
of Anaesthesiology and Intensive Care Medicine

SUPPLEMENT NR. 1 | 2023

OrphanAnesthesia –

ein krankheitsübergreifendes Projekt des Wissenschaftlichen Arbeitskreises Kinderanästhesie der Deutschen Gesellschaft für Anästhesiologie und Intensivmedizin e.V.

Ziel des Projektes ist die Veröffentlichung von Handlungsempfehlungen zur anästhesiologischen Betreuung von Patienten mit seltenen Erkrankungen. Damit will OrphanAnesthesia einen wichtigen Beitrag zur Erhöhung der Patientensicherheit leisten.

Patienten mit seltenen Erkrankungen benötigen für verschiedene diagnostische oder therapeutische Prozeduren eine anästhesiologische Betreuung, die mit einem erhöhten Risiko für anästhesieassoziierte Komplikationen einhergehen. Weil diese Erkrankungen selten auftreten, können Anästhesisten damit keine Erfahrungen gesammelt haben, so dass für die Planung der Narkose die Einholung weiterer Information unerlässlich ist. Durch vorhandene spezifische Informationen kann die Inzidenz von mit der Narkose assoziierten Komplikationen gesenkt werden. Zur Verfügung stehendes Wissen schafft Sicherheit im Prozess der Patientenversorgung.

Die Handlungsempfehlungen von OrphanAnesthesia sind standardisiert und durchlaufen nach ihrer Erstellung einen Peer-Review-Prozess, an dem ein Anästhesist sowie ein weiterer Krankheitsexperte (z.B. Pädiater oder Neurologe) beteiligt sind. Das Projekt ist international ausgerichtet, so dass die Handlungsempfehlungen grundsätzlich in englischer Sprache veröffentlicht werden.

Ab Heft 5/2014 werden im monatlichen Rhythmus je zwei Handlungsempfehlungen als Supplement der A&I unter www.ai-online.info veröffentlicht. Als Bestandteil der A&I sind die Handlungsempfehlungen damit auch zitierfähig. Sonderdrucke können gegen Entgelt bestellt werden.

OrphanAnesthesia –

a project of the Scientific Working Group of Paediatric Anaesthesia of the German Society of Anaesthesiology and Intensive Care Medicine

The target of OrphanAnesthesia is the publication of anaesthesia recommendations for patients suffering from rare diseases in order to improve patients' safety. When it comes to the management of patients with rare diseases, there are only sparse evidence-based facts and even far less knowledge in the anaesthetic outcome. OrphanAnesthesia would like to merge this knowledge based on scientific publications and proven experience of specialists making it available for physicians worldwide free of charge.

All OrphanAnesthesia recommendations are standardized and need to pass a peer review process. They are being reviewed by at least one anaesthesiologist and another disease expert (e.g. paediatrician or neurologist) involved in the treatment of this group of patients.

The project OrphanAnesthesia is internationally oriented. Thus all recommendations will be published in English.

Starting with issue 5/2014, we'll publish the OrphanAnesthesia recommendations as a monthly supplement of A&I (Anästhesiologie & Intensivmedizin). Thus they can be accessed and downloaded via www.ai-online.info. As being part of the journal, the recommendations will be quotable. Reprints can be ordered for payment.

Bisher in A&I publizierte Handlungsempfehlungen finden Sie unter:

www.ai-online.info/Orphsuppl
www.orphananesthesia.eu

Find a survey of the recommendations published until now on:

www.ai-online.info/Orphsuppl
www.orphananesthesia.eu

Projektleitung

Prof. Dr. Tino Münster, MHBA

Chefarzt
Klinik für Anästhesie und
operative Intensivmedizin
Krankenhaus Barmherzige
Brüder Regensburg
Prüfeninger Straße 86
93049 Regensburg,
Deutschland

Tel.: 0941 369-2350

E-Mail: Tino.Muenster@barmherzige-regensburg.de

orphan^aesthesia

Anaesthesia recommendations for Donohue syndrome

Disease name: Donohue syndrome

ICD 10: E34.8

Synonyms: Leprechaunism

Disease summary: Donohue syndrome is a rare autosomal recessive disorder with an incidence of 1 in 4 million live births [1,2] caused by mutations of the insulin receptor gene on chromosome 19p13 [3]. It was initially termed 'dysendocrinism' and 'leprechaunism' (owing to elf-like features of those affected) [4]; these terms have since been discarded in favour of Donohue syndrome.

The primary pathology is insulin resistance due to defective binding of insulin to its mutant receptor. These insulin receptor mutations are often collectively termed 'loss of function' mutations. Multiple mutations have been identified and the natural history of the disease depends on the degree of insulin resistance [5]. While patients with milder forms (the most common of which is Rabson-Mendelhall syndrome) can live into adulthood, a severe disease results in death during infancy. Clinical features include growth retardation (intrauterine growth restriction, low birth weight, marasmus, failure to thrive), organomegaly (liver, spleen, kidneys, genitals), abnormal facies (pointed chin, microcephaly, prominent low set ears), skin features (pachyderma, hypertrichosis, acanthosis nigricans), hypotonia and relatively large hands/feet. Accelerated fasting states cause muscle wasting and low subcutaneous fat. They may also have hyperplasia of the islets of Langerhans, nephrocalcinosis, atrophic adrenal glands, bile duct cholestasis, lymphoid hypoplasia and cystic gonadal appearances. Cardiac involvement in the form of hypertrophic cardiomyopathy, which occurs early in infancy, is attributed to the effects of IGF-1 [6]. A pathognomonic biochemical triad includes hyperinsulinism, fasting hypoglycaemia and postprandial hyperglycaemia [3].

Infants with the severe variant have a poor prognosis, succumbing to sepsis due to immunodeficiency. There is no established curative treatment, but exogenous administration of IGF-1 can be used in all insulin resistance syndromes to improve glycaemic control, to reduce levels of hyperinsulinaemia and the secondary effects of hyperinsulinism.

Medicine is in progress



Perhaps new knowledge

Every patient is unique

Perhaps the diagnosis is wrong



Find more information on the disease, its centres of reference and patient organisations on Orphanet: www.orpha.net

► **Citation:** Shihurkar R, Stuart G: Donohue syndrome. AnästH Intensivmed 2023;64:S14–S19.
DOI: 10.19224/ai2023.S014

Typical surgery

Central venous access, endoscopy, MRI, gastrostomy insertion, laparotomy.

Type of anaesthesia

Considering the risks associated, it should be ensured that the benefits of surgery justify administering anaesthesia.

General anaesthesia is described in the literature and concerns revolve around the management of the difficult airway, cardiomyopathy and unstable blood glucose [7].

There are no reports of using regional anaesthesia in these patients, however, neuraxial or peripheral nerve blocks are not contraindicated in Donohue syndrome. Concerns, preparation and precautions are similar to general anaesthesia.

The benefits of sedation must be carefully weighed against the risk of a difficult airway, haemodynamic instability and hypoglycaemia while asleep. Anaesthetic backup should be immediately available if needed.

Necessary additional preoperative testing (beside standard care)

Fasting causes severe hypoglycaemia in Donohue syndrome, hence a short preoperative fasting time and glucose-containing intravenous maintenance fluids should be considered. Frequent blood sugar monitoring is essential in the perioperative setting.

Preoperative echocardiography is indicated as cardiomyopathy, which often exists by 1–2 months of age, may not be clinically manifest [8,9].

Particular preparation for airway management

Difficult airway should be anticipated even in patients with previously normal airways. Small thoracic diameter, poor chest compliance and abdominal distension result in low functional residual capacity and oxygen reserves which cause rapid desaturations. Bag mask ventilation may require a two-person technique and intubation can be challenging due to small mouth size. Adequate preparation includes difficult airway equipment, laryngeal mask airways, an experienced second anaesthetist and available ENT assistance with the ability to insert a rigid bronchoscope or tracheostomy if necessary [7].

It must be remembered that airway management could continue to be challenging during or after extubation.

Particular preparation for transfusion or administration of blood products

Owing to their small size and low physiologic reserve, small volume blood loss in these children may result in significant haemodynamic instability. It is prudent to ensure swift availability of blood products for transfusion.

Particular preparation for anticoagulation

No theoretical concerns with coagulation, but where organomegaly is a feature, liver functions and coagulation should be assessed preoperatively.

Particular precautions for positioning, transportation and mobilisation

The patient may need special care with movement and positioning due to an abnormal body habitus and small restrictive chest.

Interactions of chronic disease and anaesthesia medications

Careful induction is warranted as hypertrophic cardiomyopathy predisposes these children to cardiovascular instability and arrest.

Anaesthetic procedure

Intravenous access and nasogastric tube should be secured before or soon after induction. Gastric contents should be aspirated before and during bag mask ventilation to minimise abdominal distension. Inhalational induction with spontaneous ventilation is recommended as it minimises gastric insufflation and the apnoeic period. Nitrous oxide should be avoided to optimise oxygenation in view of a potentially difficult airway, poor functional residual capacity and an underlying cardiomyopathy.

Intravenous induction, if done, should be titrated gradually to effect. A technique combining opiates, benzodiazepines and ketamine allows induction to proceed without sudden changes in heart rate, blood pressure and cardiac output.

These children mount a normal stress response to surgery, hence intraoperative glycaemic control should be individualised with frequent blood sugar measurements.

Hepatobiliary compromise must be factored in while assessing drug metabolism. Nephrotoxic drugs and NSAIDs must be avoided in patients with nephrocalcinosis and renal tubular dysfunction.

Particular or additional monitoring

Invasive haemodynamic monitoring with central venous pressure and invasive arterial blood pressure may be required for patients with cardiomyopathy and/or procedures involving fluid shifts or haemodynamic fluctuations.

Possible complications

1. Difficult airway including difficult mask ventilation, difficult intubation and difficult extubation,
2. Desaturation and hypoxic arrest,
3. Haemodynamic instability leading to cardiac arrest,
4. Hypoglycaemia and/or hyperglycaemia.

Postoperative care

Preparation for difficult airway (personnel, equipment, drugs) should be maintained in the immediate postoperative period.

Close glycaemic monitoring and control is essential to prevent hypo-/hyperglycaemia. Combined with scrupulous antisepsis, normoglycaemia aids wound healing and avoids infections in a child with compromised immunity.

These patients must be cared for in a multidisciplinary setting where specialist input (endocrinology or cardiology for example) is readily accessible.

Disease-related acute problems and effect on anaesthesia and recovery

1. Fasting hypoglycaemia: symptoms are masked under anaesthesia and complications may occur if not detected and managed.
2. Delayed recovery from the effects of neuromuscular blockade and/or opiates: due to muscle wasting, low fat reserves and increased sensitivity in the setting of failure to thrive.

Ambulatory anaesthesia

Not feasible as these patients need intravenous fluid therapy and close monitoring of glycaemic control.

Obstetrical anaesthesia

Not reported.

References

1. Mohamed S. An infant with Leprechaunism, ambiguous genitalia and poor glycaemic control: a management challenge. *Acta Endocrinol (Buc)* 2014;10:134–139
2. Martínez-Frías M, Bermejo E, Rodríguez-Pinilla E, Martínez-Fernández ML. Síndrome de Donohue (Leprechaunismo). *ECEMC* 2010;24:1–2
3. Nijim Y, Awni Y, Adawi A, Bowirrat A. Classic Case Report of Donohue Syndrome (Leprechaunism; OMIM *246200): The Impact of Consanguineous Mating. *Medicine (Baltimore)* 2016;95:e2710
4. Online Mendelian Inheritance in Man (OMIM) Insulin Receptor -147670. https://www.omim.org/search?index=entry&start=1&limit=10&sort=score+desc%2C+prefix_sor t+desc&search=147670 (accessed on: 12.02.2021)
5. Longo N, Wang Y, Smith SA, Langley SD, DiMeglio LA, Giannella-Neto D. Genotype–phenotype correlation in inherited severe insulin resistance. *Hum Mol Genet* 2002;11:1465–1475
6. Hovnik T, Bratanič N, Podkrajšek KT, et al: Severe progressive obstructive cardiomyopathy and renal tubular dysfunction in Donohue syndrome with decreased insulin receptor autophosphorylation due to a novel INSR mutation. *Eur J Pediatr* 2013;172:1125
7. Kirkwood A, Stuart G, Harding L. Donohue syndrome: A review of literature, case series, and anesthetic considerations. *Pediatr Anesth* 2018;28:23–27
8. Planchenault D, Martin-Coignard D, Rugemintwazac D. Le syndrome de Donohue ou leprechaunisme: a propos d'un cas. *Arch Pediatr* 2014;21:206–210
9. Baykan A, Cansever M, Konuskan B. Hypertrophic cardiomyopathy with leprechaunism. *J Pediatr Endocrinol Metab* 2008;21:317–318.

Date last modified: **March 2021**

Authors:

Ravi Shihurkar, Paediatric anaesthesiologist, Great Ormond Street Hospital for Children, London, United Kingdom
ravi.shihurkar@gmail.com

Grant Stuart, Paediatric anaesthesiologist, Great Ormond Street Hospital for Children, London, United Kingdom

Disclosure The authors have no financial or other competing interest to disclose. This recommendation was unfunded.

Reviewers:

Carlos Degrandi, Anaesthesiologist, Hospital Guilherme Álvaro, Santos, Brazil
degrandi@gmail.com

Alana Kirkwood, Paediatric anaesthesiologist, Royal Hospital for Children, Glasgow, Scotland, United Kingdom
alana.kirkwood1@nhs.net

Please note that this recommendation was not reviewed by an anaesthesiologist and a disease expert but by two anaesthesiologists instead.

Disclosure The reviewers have no financial or other competing interest to disclose.

Herausgeber



DGAI

Deutsche Gesellschaft
für Anästhesiologie und
Intensivmedizin e.V.
Präsident: Prof. Dr.
B. Pannen, Düsseldorf



BDA

Berufsverband Deutscher
Anästhesisten e.V.
Präsident: Prof. Dr.
G. Geldner, Ludwigsburg †

Schriftleitung

Präsident/in der Herausgeberverbände
Gesamtschriftleiter/Editor-in-Chief:
Prof. Dr. Dr. Kai Zacharowski,
ML FRCA FESAIC, Frankfurt
Stellvertretender Gesamtschriftleiter/
Deputy Editor:
Prof. Dr. T. Volk, Homburg/Saar
CME-Schriftleiter/CME-Editor:
Prof. Dr. W. Zink, Ludwigshafen

Redaktionskomitee/Editorial Board

Prof. Dr. G. Beck, Wiesbaden
Prof. Dr. A. Brinkmann, Heidenheim
Prof. Dr. H. Bürkle, Freiburg
Prof. Dr. B. Ellger, Dortmund
Prof. Dr. K. Engelhard, Mainz
Prof. Dr. M. Fischer, Göppingen
Prof. Dr. U. X. Kaisers, Ulm
Prof. Dr. T. Loop, Freiburg
Prof. Dr. W. Meißner, Jena
Prof. Dr. C. Nau, Lübeck
RAin A. Pfundstein, Nürnberg
Dr. M. Rähmer, Mainz
Prof. Dr. A. Schleppers, Nürnberg
Prof. Dr. M. Thiel, Mannheim
Prof. Dr. F. Wappler, Köln
Prof. Dr. M. Weigand, Heidelberg

Redaktion/Editorial Staff

Carolin Sofia Kopp B.A.
Korrespondenzadresse:
Neuwieder Straße 9 | 90411 Nürnberg |
Deutschland | Tel.: 0911 9337812
E-Mail: anaesth.intensivmed@dgai-ev.de

Verlag & Druckerei

Aktiv Druck & Verlag GmbH

An der Lohwiese 36 |
97500 Ebelsbach | Deutschland
www.aktiv-druck.de



Geschäftsführung

Wolfgang Schröder | Jan Schröder |
Nadja Schwarz
Tel.: 09522 943560 | Fax: 09522 943567
E-Mail: info@aktiv-druck.de

Anzeigen | Vertrieb

Pia Müller | Robert Kux
Tel.: 09522 943570 | Fax: 09522 943577
E-Mail: anzeigen@aktiv-druck.de

Verlagsrepräsentanz

Jürgen Distler
Neuwieder Straße 9 | 90411 Nürnberg
Tel.: 0171 9432534
E-Mail: jdistler@bda-ev.de

Herstellung | Gestaltung

Pia Müller | Robert Kux |
Stefanie Triebert
Tel.: 09522 943570 | Fax: 09522 943577
E-Mail: ai@aktiv-druck.de

Titelbild

Gestaltung: Klaus Steigner
Paumgartnerstraße 28 | 90429 Nürnberg
E-Mail: mazyblue@klaus-steigner.de
www.klaus-steigner.de

Erscheinungsweise 2023

Der 64. Jahrgang erscheint jeweils zum
Monatsanfang, Heft 7/8 als Doppelausgabe.

Bezugspreise (inkl. Versandkosten):

• Einzelhefte	30,- €
• Jahresabonnement:	
Europa (ohne Schweiz)	258,- €
(inkl. 7 % MwSt.)	
Schweiz	266,- €
Rest der Welt	241,- €

Mitarbeiter aus Pflege, Labor, Studenten und Auszubildende (bei Vorlage eines entsprechenden Nachweises)

Europa (ohne Schweiz)	94,- €
(inkl. 7 % MwSt.)	
Schweiz	90,- €
Rest der Welt	94,- €

**Für Mitglieder der DGAI und/oder
des BDA ist der Bezug der Zeitschrift
im Mitgliedsbeitrag enthalten.**

Allgemeine Geschäfts- und Liefer- bedingungen

Die allgemeinen Geschäfts- und Liefer-
bedingungen entnehmen Sie bitte dem
Impressum auf www.ai-online.info

Indexed in **Current Contents®/Clinical
Medicine, EMBASE/Excerpta Medica;
Medical Documentation Service;
Research Alert; Sci Search; SUBIS
Current Awareness in Biomedicine;
VINITI: Russian Academy of Science.**

Nachdruck | Urheberrecht

Die veröffentlichten Beiträge sind urhe-
berrechtlich geschützt. Jegliche Art von
Vervielfältigungen – sei es auf mechani-
chem, digitalem oder sonst möglichem
Wege – bleibt vorbehalten. Die Aktiv
Druck & Verlags GmbH ist allein auto-
risiert, Rechte zu vergeben und Sonder-
drucke für gewerbliche Zwecke, gleich
in welcher Sprache, herzustellen. An-
fragen hierzu sind nur an den Verlag zu
richten. Jede im Bereich eines gewerbli-
chen Unternehmens zulässig hergestellte
oder benutzte Kopie dient gewerblichen
Zwecken gem. § 54 (2) UrhG. Die Wie-
dergabe von Gebrauchsnamen, Handels-
namen, Warenbezeichnungen usw. in
dieser Zeitschrift berechtigt auch ohne
besondere Kennzeichnung nicht zu der
Annahme, dass solche Namen im Sinne
der Warenzeichen- und Markenschutz-
Gesetzgebung als frei zu betrachten wä-
ren und daher von jedermann benutzt
werden dürften.

Wichtiger Hinweis

Für Angaben über Dosierungsanwei-
sungen und Applikationsformen kann
vom Verlag und den Herausgebern keine
Gewähr übernommen werden. Derartige
Angaben müssen vom jeweiligen An-
wender im Einzelfall anhand anderer
Literaturstellen auf ihre Richtigkeit über-
prüft werden. Gleiches gilt für berufs-
und verbandspolitische Stellungnahmen
und Empfehlungen.

Allein aus Gründen der besseren Les-
barkeit wird auf die gleichzeitige Ver-
wendung männlicher, weiblicher und
weiterer Sprachformen verzichtet. Sämt-
liche Personenbezeichnungen gelten für
alle Geschlechterformen. Dies impliziert
keinesfalls eine Benachteiligung der je-
weils anderen Geschlechter, sondern ist
als geschlechtsneutral zu verstehen.

Die Beiträge aus der A&I
finden Sie online unter:
www.ai-online.info

CONTACT US

Please do not hesitate to contact us. We will be glad to answer and provide further information to you at any time.

.....
Name

.....
First Name

.....
Department / Hospital

.....
Place

.....
Telephone

.....
E-Mail

.....
Date / Signature

Please contact me for further information

☐

I would like to participate in the project

☐

ADDRESS

German Society of Anaesthesiology and
Intensive Care Medicine
Ursula Homberg
Neuwieder Straße 9 | 90411 Nuremberg | Germany
Tel.: +49-911-9337828
Email: uhomberg@orphananesthesia.eu